<--- Back to Details
First PageDocument Content
Medicine / Immunosuppressants / Immunology / Clinical medicine / Monoclonal antibodies / Cytokines / Therapeutic antibodies / Autoimmune diseases / Infliximab / Anakinra / Adalimumab / Interferon
Date: 2015-08-17 11:45:03
Medicine
Immunosuppressants
Immunology
Clinical medicine
Monoclonal antibodies
Cytokines
Therapeutic antibodies
Autoimmune diseases
Infliximab
Anakinra
Adalimumab
Interferon

EAP Reimbursement Criteria for Frequently Requested Drugs

Add to Reading List

Source URL: www.health.gov.on.ca

Download Document from Source Website

File Size: 1,22 MB

Share Document on Facebook

Similar Documents

INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy

INTERNSHIP PROPOSAL Institute and Group: IBS group HIV and persistent human viruses Supervisor: Pascal Poignard Email: Research project title: Human monoclonal antibodies: a new therapeutic strategy

DocID: 1uPEI - View Document

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra,

Visterra Acquires Exclusive Patent License for Monoclonal Antibodies against Dengue Virus from MIT – Expands Company’s Therapeutic Pipeline for Infectious Diseases – Cambridge, MA – December 2, 2013 – Visterra,

DocID: 1ujGa - View Document

EAP Reimbursement Criteria for Frequently Requested Drugs

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

24 MayDanae Staples-Moon Therapeutic Group Manager PHARMAC PO Box

24 MayDanae Staples-Moon Therapeutic Group Manager PHARMAC PO Box

DocID: 1qVSm - View Document

12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box

12 JulyGeraldine MacGibbon Senior Therapeutic Group Manager PHARMAC PO Box

DocID: 1qIwe - View Document